Psychiatry and Clinical Psychopharmacology (Jan 2017)

Serum peroxisome proliferator-activated receptor-gamma levels in acute phase of male patients with schizophrenia and their relationship with metabolic parameters

  • Tevfik Kalelioglu,
  • Nurdan Durak,
  • Nesrin Karamustafalioglu,
  • Abdullah Genc,
  • Mustafa Akkus,
  • Akif Tasdemir,
  • Cem Mehmet Ilnem

DOI
https://doi.org/10.1080/24750573.2017.1293244
Journal volume & issue
Vol. 27, no. 1
pp. 30 – 34

Abstract

Read online

Objective: Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor family providing the modulation of the genes having a role in gluco-lipid metabolism and inflammation. Here, we aimed to compare serum PPARγ levels between medication-free schizophrenia patients and healthy controls. Methods: Forty-five inpatients with schizophrenia and 39 healthy controls were included in the study. Serum PPARγ levels and metabolic syndrome (MetS) parameters of the patients and controls were compared. Results: There were no statistically significant differences between the patients (1.42 ± 0.64 ng/ml) and the control group (1.59 ± 1.10 ng/ml) in terms of serum PPARγ levels. No statistically significant correlations were determined between the MetS parameters and PPARγ levels. Conclusions: Our findings showed that PPARγ, which we predicted to have a role in metabolic disorders and inflammatory process in schizophrenia, did not seem to have a role in the acute exacerbation of schizophrenia.

Keywords